MX2011009312A - Formulaciones de anticuerpos humanizados anti-cd19. - Google Patents

Formulaciones de anticuerpos humanizados anti-cd19.

Info

Publication number
MX2011009312A
MX2011009312A MX2011009312A MX2011009312A MX2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A MX 2011009312 A MX2011009312 A MX 2011009312A
Authority
MX
Mexico
Prior art keywords
humanized anti
antibody formulations
cdc
apoptosis
chimeric
Prior art date
Application number
MX2011009312A
Other languages
English (en)
Inventor
Monika Sharma
Ambarish Shah
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2011009312A publication Critical patent/MX2011009312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención concierne a formulaciones líquidas estables que comprenden versiones quiméricas y humanizadas de anticuerpos monoclonales de ratón anti-CD19 adecuados para mediar ADCC, la CDC y/o la apoptosis para el tratamiento de las enfermedades y desordenes de las células B.
MX2011009312A 2009-03-06 2010-03-08 Formulaciones de anticuerpos humanizados anti-cd19. MX2011009312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15815309P 2009-03-06 2009-03-06
PCT/US2010/026492 WO2010102276A2 (en) 2009-03-06 2010-03-08 Humanized anti-cd19 antibody formulations

Publications (1)

Publication Number Publication Date
MX2011009312A true MX2011009312A (es) 2012-02-29

Family

ID=42710248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009312A MX2011009312A (es) 2009-03-06 2010-03-08 Formulaciones de anticuerpos humanizados anti-cd19.

Country Status (12)

Country Link
US (1) US20120148576A1 (es)
EP (1) EP2403532A4 (es)
JP (1) JP2012519712A (es)
KR (1) KR20110125664A (es)
CN (1) CN102413839A (es)
AU (1) AU2010221099A1 (es)
BR (1) BRPI1013237A2 (es)
CA (1) CA2754266A1 (es)
MX (1) MX2011009312A (es)
RU (1) RU2011140486A (es)
WO (1) WO2010102276A2 (es)
ZA (1) ZA201106480B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
HRP20171095T4 (hr) * 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
EP2793941A1 (en) * 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
RU2014141056A (ru) * 2012-03-12 2016-05-10 МЕДИММЬЮН, ЭлЭлСи Лечение рассеянного склероза при помощи антитела к cd19
JP2015520625A (ja) * 2012-04-23 2015-07-23 ゾゲニクス インコーポレーティッド 薬物送達カプセルのためのピストン施栓
AU2013289984B2 (en) * 2012-07-13 2018-03-08 The Trustees Of The University Of Pennsylvania Use of CART19 to deplete normal B cells to induce tolerance
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
AU2014243783B2 (en) * 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
CN106132434A (zh) * 2014-04-07 2016-11-16 西雅图基因公司 抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
EP3149046B1 (en) * 2015-07-24 2020-02-26 Innovative Cellular Therapeutics Co., Ltd. Humanized anti-cd19 antibody and use thereof
DK3475303T3 (da) * 2016-06-27 2021-05-31 Morphosys Ag Anti-cd19-antistofformuleringer
EP3330289A1 (en) * 2016-12-02 2018-06-06 Friedrich-Alexander-Universität Erlangen-Nürnberg A cd33-, cd16- and cd123-specific single chain triplebody
KR102417583B1 (ko) 2017-03-02 2022-07-07 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
US11534462B2 (en) 2017-12-06 2022-12-27 Abclon Inc. Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
BR112021020924A2 (pt) * 2019-04-24 2022-04-19 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar doença autoimune
JP2022550435A (ja) 2019-10-04 2022-12-01 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えａａｖの改善された治療的使用のための方法
CN116234576A (zh) * 2020-07-31 2023-06-06 阿拉玛布治疗学股份有限公司 抗-连接蛋白抗体制剂
KR20230127292A (ko) * 2020-12-30 2023-08-31 아이-맵 바이오파마 컴파니 리미티드 항-cd73 항체의 제제
CN113208810B (zh) * 2021-05-18 2022-04-12 南方医科大学深圳医院 一种用于smile术透镜染色低温分离液的超声波给药装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
EP2066349B1 (en) * 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases

Also Published As

Publication number Publication date
KR20110125664A (ko) 2011-11-21
BRPI1013237A2 (pt) 2019-09-24
RU2011140486A (ru) 2013-04-20
CA2754266A1 (en) 2010-09-10
AU2010221099A1 (en) 2011-09-22
EP2403532A2 (en) 2012-01-11
JP2012519712A (ja) 2012-08-30
EP2403532A4 (en) 2012-12-05
ZA201106480B (en) 2012-06-27
US20120148576A1 (en) 2012-06-14
WO2010102276A3 (en) 2010-11-11
CN102413839A (zh) 2012-04-11
WO2010102276A2 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
NL301196I2 (nl) inebilizumab
PH12018501554A1 (en) Ror1 antibody compositions and related methods
GEP20227438B (en) Pd-1-binding molecules and methods of use thereof
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
EP3712178A4 (en) ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
EA201792221A1 (ru) Антитела против сортилина и способы их применения
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TN2014000107A1 (en) Anti-aplhabetatcr antibody
UA92504C2 (en) Anti-myostatin monoclonal antibody
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
PH12014501338A1 (en) Chimeric therapeutic anti-cd37 antibodie hh1
AU2013232386A8 (en) Treatment of multiple sclerosis with anti-CD19 antibody
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal